For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

You are here

Publications

Found 59 results
Author Title [ Type(Desc)] Year
Filters: Author is Nathan, Carl F  [Clear All Filters]
Journal Article
Zhan W, Hsu H-C, Morgan T, Ouellette T, Burns-Huang K, Hara R, Wright AG, Imaeda T, Okamoto R, Sato K et al..  2019.  Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome.. J Med Chem. 62(20):9246-9253.
Mosior J, Bourland R, Soma S, Nathan C, Sacchettini J.  2019.  Structural insights into phosphopantetheinyl hydrolase PptH from Mycobacterium tuberculosis.. Protein Sci.
Santos Rde Luna Al, Bai L, Singh PK, Murakami N, Fan H, Zhan W, Zhu Y, Jiang X, Zhang K, Assker JPierre et al..  2017.  Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes.. Nat Commun. 8(1):1692.
Nathan C.  2009.  Taming tuberculosis: a challenge for science and society.. Cell Host Microbe. 5(3):220-4.
Zhao N, Darby CM, Small J, Bachovchin DA, Jiang X, Burns-Huang KE, Botella H, Ehrt S, Boger DL, Anderson ED et al..  2015.  Target-based screen against a periplasmic serine protease that regulates intrabacterial pH homeostasis in Mycobacterium tuberculosis.. ACS Chem Biol. 10(2):364-71.
Gold B, Nathan C.  2017.  Targeting Phenotypically Tolerant Mycobacterium tuberculosis.. Microbiol Spectr. 5(1)
Nathan C, Barry CE.  2015.  TB drug development: immunology at the table.. Immunol Rev. 264(1):308-18.
Zhang L, Jiang X, Pfau D, Ling Y, Nathan CF.  2021.  Type I interferon signaling mediates Mycobacterium tuberculosis-induced macrophage death.. J Exp Med. 218(2)
Nathan C.  2015.  What can immunology contribute to the control of the world's leading cause of death from bacterial infection? Immunol Rev. 264(1):2-5.